 | • レポートコード：MRC2401A124 • 出版社/出版日：Transparency Market Research / 2023年11月 • レポート形態：英文、PDF、289ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ワクチン市場-レポート範囲 TMRの調査レポート「世界のワクチン市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界のワクチン市場の収益を提供しています。また、2023年から2031年までの世界のワクチン市場の複合年間成長率（CAGR %）も掲載しています。 本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、ワクチン市場を理解しました。 二次調査には、インターネットソース、政府機関の統計データ、ウェブサイト、業界団体なども含まれます。アナリストはトップダウンアプローチとボトムアップアプローチを組み合わせて、世界のワクチン市場の様々な属性を調査しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは世界のワクチン市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場プレイヤーだけでなく、世界のワクチン市場への参入に関心のある企業にとっても貴重なツールとなります。 本レポートでは、世界のワクチン市場の競争状況について掘り下げています。世界のワクチン市場で事業を展開する主要プレイヤーを特定し、各プレイヤーを様々な属性でプロファイルしています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のワクチン市場におけるプレイヤーの属性です。 世界のワクチン市場レポートで回答された主な質問 - 予測期間中の全地域におけるワクチンの売上高/収益は？ - 世界のワクチン市場におけるビジネスチャンスは？ - 市場の主な促進要因、阻害要因、機会、脅威は？ - 予測期間中に最も速いCAGRで拡大する地域市場は？ - 2031年に世界で最も高い収益を上げると予測されるセグメントは？ - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは？ - 世界市場で事業を展開する各企業の市場ポジションは？ 調査目的・調査アプローチ 世界のワクチン市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。 本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフと表を適切に配置した網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化することで、読者に視覚的に訴えかけます。また、主要セグメントの過去と予測期間末の市場シェアの比較も可能です。 本レポートでは、世界のワクチン市場を製品、エンドユーザー、地域の観点から分析。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界ワクチン市場への投資について十分な情報に基づいたビジネス上の意思決定を行うことができます。 |
1. 序論
2. 仮定・調査方法
3. エグゼクティブサマリー：世界のワクチン市場
4. 市場概要
5. 主要インサイト
6. 世界のワクチン市場分析・予測：車両別
7. 世界のワクチン市場分析・予測：バランス別
8. 世界のワクチン市場分析・予測：投与経路別
9. 世界のワクチン市場分析・予測：疾患別
10. 世界のワクチン市場分析・予測：流通チャネル別
11. 世界のワクチン市場分析・予測：地域別
12. 北米のワクチン市場分析・予測
13. ヨーロッパのワクチン市場分析・予測
14. アジア太平洋のワクチン市場分析・予測
15. 中南米のワクチン市場分析・予測
16. 中東・アフリカのワクチン市場分析・予測
17. 競争状況
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vaccines Market
4. Market Overview
4.1. Introduction
4.2. Definition
4.3. Industry Evolution / Developments
4.4. Overview
4.5. Market Dynamics
4.5.1. Drivers
4.5.2. Restraints
4.5.3. Opportunities
4.6. Global Vaccines Market Analysis and Forecast, 2017-2031
4.6.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario
5.2. Key Distribution Strategies
5.3. Pricing Analysis
5.4. Patents on Vaccines
5.5. Technological Advancements in Vaccines
5.6. Vaccine Type – Overview
5.7. COVID-19 Pandemic Impact on Industry
6. Global Vaccines Market Analysis and Forecast, by Vaccine
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Vaccine, 2017-2031
6.3.1. Inactivated
6.3.2. Live Attenuated
6.3.3. Toxoid
6.3.4. Conjugate
6.3.5. Others
6.4. Market Attractiveness Analysis, by Vaccine
7. Global Vaccines Market Analysis and Forecast, by Valance
7.1. Introduction & Definition
7.2. Developments
7.3. Market Value Forecast, by Valance, 2017-2031
7.3.1. Monovalent
7.3.2. Multivalent
7.4. Market Attractiveness Analysis, by Valance
8. Global Vaccines Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
8.3.1. Oral
8.3.2. Injectable
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Vaccines Market Analysis and Forecast, by Indication
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Indication, 2017-2031
9.3.1. Influenza
9.3.2. Hepatitis
9.3.3. Polio
9.3.4. Meningococcal Disease
9.3.5. Pneumococcal Disease
9.3.6. DTP
9.3.7. Rotavirus
9.3.8. MMR
9.3.9. Human Papilloma Virus
9.3.10. Others
9.4. Market Attractiveness Analysis, by Indication
10. Global Vaccines Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2017-2031
10.3.1. Institutional Sales
10.3.2. Hospital Pharmacies
10.3.3. Retail Pharmacies
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Vaccines Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017-2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Vaccines Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Vaccine, 2017-2031
12.3.1. Inactivated
12.3.2. Live Attenuated
12.3.3. Toxoid
12.3.4. Conjugate
12.3.5. Others
12.4. Market Value Forecast, by Valance, 2017-2031
12.4.1. Monovalent
12.4.2. Multivalent
12.5. Market Value Forecast, by Route of Administration, 2017-2031
12.5.1. Oral
12.5.2. Injectable
12.5.3. Others
12.6. Market Value Forecast, by Indication, 2017-2031
12.6.1. Influenza
12.6.2. Hepatitis
12.6.3. Polio
12.6.4. Meningococcal Disease
12.6.5. Pneumococcal Disease
12.6.6. DTP
12.6.7. Rotavirus
12.6.8. MMR
12.6.9. Human Papilloma Virus
12.6.10. Others
12.7. Market Value Forecast, by Distribution Channel, 2017-2031
12.7.1. Institutional Sales
12.7.2. Hospital Pharmacies
12.7.3. Retail Pharmacies
12.8. Market Value Forecast, by Country/sub-region, 2017-2031
12.8.1. U.S.
12.8.2. Canada
12.9. Market Attractiveness Analysis
12.9.1. By Vaccine
12.9.2. By Valance
12.9.3. By Route of Administration
12.9.4. By Indication
12.9.5. By Distribution Channel
12.9.6. By Country
13. Europe Vaccines Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Vaccine, 2017-2031
13.3.1. Inactivated
13.3.2. Live Attenuated
13.3.3. Toxoid
13.3.4. Conjugate
13.3.5. Others
13.4. Market Value Forecast, by Valance, 2017-2031
13.4.1. Monovalent
13.4.2. Multivalent
13.5. Market Value Forecast, by Route of Administration, 2017-2031
13.5.1. Oral
13.5.2. Injectable
13.5.3. Others
13.6. Market Value Forecast, by Indication, 2017-2031
13.6.1. Influenza
13.6.2. Hepatitis
13.6.3. Polio
13.6.4. Meningococcal Disease
13.6.5. Pneumococcal Disease
13.6.6. DTP
13.6.7. Rotavirus
13.6.8. MMR
13.6.9. Human Papilloma Virus
13.6.10. Others
13.7. Market Value Forecast, by Distribution Channel, 2017-2031
13.7.1. Institutional Sales
13.7.2. Hospital Pharmacies
13.7.3. Retail Pharmacies
13.8. Market Value Forecast, by Country/sub-region, 2017-2031
13.8.1. Germany
13.8.2. U.K.
13.8.3. France
13.8.4. Italy
13.8.5. Spain
13.8.6. Rest of Europe
13.9. Market Attractiveness Analysis
13.9.1. By Vaccine
13.9.2. By Valance
13.9.3. By Route of Administration
13.9.4. By Indication
13.9.5. By Distribution Channel
13.9.6. By Country/Sub-region
14. Asia Pacific Vaccines Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Vaccine, 2017-2031
14.3.1. Inactivated
14.3.2. Live Attenuated
14.3.3. Toxoid
14.3.4. Conjugate
14.3.5. Others
14.4. Market Value Forecast, by Valance, 2017-2031
14.4.1. Monovalent
14.4.2. Multivalent
14.5. Market Value Forecast, by Route of Administration, 2017-2031
14.5.1. Oral
14.5.2. Injectable
14.5.3. Others
14.6. Market Value Forecast, by Indication, 2017-2031
14.6.1. Influenza
14.6.2. Hepatitis
14.6.3. Polio
14.6.4. Meningococcal Disease
14.6.5. Pneumococcal Disease
14.6.6. DTP
14.6.7. Rotavirus
14.6.8. MMR
14.6.9. Human Papilloma Virus
14.6.10. Others
14.7. Market Value Forecast, by Distribution Channel, 2017-2031
14.7.1. Institutional Sales
14.7.2. Hospital Pharmacies
14.7.3. Retail Pharmacies
14.8. Market Value Forecast, by Country/sub-region, 2017-2031
14.8.1. China
14.8.2. India
14.8.3. Japan
14.8.4. Australia & New Zealand
14.8.5. Rest of Asia Pacific
14.9. Market Attractiveness Analysis
14.9.1. By Vaccine
14.9.2. By Valance
14.9.3. By Route of Administration
14.9.4. By Indication
14.9.5. By Distribution Channel
14.9.6. By Country/Sub-region
15. Latin America Vaccines Market Analysis and Forecast
15.1. Introduction
15.2. Key Findings
15.3. Market Value Forecast, by Vaccine, 2017-2031
15.3.1. Inactivated
15.3.2. Live Attenuated
15.3.3. Toxoid
15.3.4. Conjugate
15.3.5. Others
15.3.6. Others
15.4. Market Value Forecast, by Valance, 2017-2031
15.4.1. Monovalent
15.4.2. Multivalent
15.5. Market Value Forecast, by Route of Administration, 2017-2031
15.5.1. Oral
15.5.2. Injectable
15.5.3. Others
15.6. Market Value Forecast, by Indication, 2017-2031
15.6.1. Influenza
15.6.2. Hepatitis
15.6.3. Polio
15.6.4. Meningococcal Disease
15.6.5. Pneumococcal Disease
15.6.6. DTP
15.6.7. Rotavirus
15.6.8. MMR
15.6.9. Human Papilloma Virus
15.6.10. Others
15.7. Market Value Forecast, by Distribution Channel, 2017-2031
15.7.1. Institutional Sales
15.7.2. Hospital Pharmacies
15.7.3. Retail Pharmacies
15.8. Market Value Forecast, by Country/sub-region, 2017-2031
15.8.1. Brazil
15.8.2. Mexico
15.8.3. Rest of Latin America
15.9. Market Attractiveness Analysis
15.9.1. By Vaccine
15.9.2. By Valance
15.9.3. By Route of Administration
15.9.4. By Indication
15.9.5. By Distribution Channel
15.9.6. By Country/Sub-region
16. Middle East & Africa Vaccines Market Analysis and Forecast
16.1. Introduction
16.2. Key Findings
16.3. Market Value Forecast, by Vaccine, 2017-2031
16.3.1. Inactivated
16.3.2. Live Attenuated
16.3.3. Toxoid
16.3.4. Conjugate
16.3.5. Others
16.4. Market Value Forecast, by Valance, 2017-2031
16.4.1. Monovalent
16.4.2. Multivalent
16.5. Market Value Forecast, by Route of Administration, 2017-2031
16.5.1. Oral
16.5.2. Injectable
16.5.3. Others
16.6. Market Value Forecast, by Indication, 2017-2031
16.6.1. Influenza
16.6.2. Hepatitis
16.6.3. Polio
16.6.4. Meningococcal Disease
16.6.5. Pneumococcal Disease
16.6.6. DTP
16.6.7. Rotavirus
16.6.8. MMR
16.6.9. Human Papilloma Virus
16.6.10. Others
16.7. Market Value Forecast, by Distribution Channel, 2017-2031
16.7.1. Institutional Sales
16.7.2. Hospital Pharmacies
16.7.3. Retail Pharmacies
16.8. Market Value Forecast, by Country/sub-region, 2017-2031
16.8.1. GCC Countries
16.8.2. South Africa
16.8.3. Rest of Middle East & Africa
16.9. Market Attractiveness Analysis
16.9.1. By Vaccine
16.9.2. By Valance
16.9.3. By Route of Administration
16.9.4. By Indication
16.9.5. By Distribution Channel
16.9.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. AstraZeneca
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. GlaxoSmithKline PLC
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Sanofi Pasteur SA
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Pfizer Inc.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Panacea Biotec
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Merck & Co., Inc.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Janssen Pharmaceutical Company
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Serus Institute of India Ltd
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Emergent BioSolutions Inc.
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. CSL
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
17.3.11. Bavarian Nordic
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Product Portfolio
17.3.11.3. Financial Overview
17.3.11.4. SWOT Analysis
17.3.11.5. Strategic Overview
17.3.12. IBSS BIOMED S.A.
17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.12.2. Product Portfolio
17.3.12.3. Financial Overview
17.3.12.4. SWOT Analysis
17.3.12.5. Strategic Overview
17.3.13. Novavax AB
17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.13.2. Product Portfolio
17.3.13.3. Financial Overview
17.3.13.4. SWOT Analysis
17.3.13.5. Strategic Overview
17.3.14. Mitsubishi Tanabe Pharma Corporation
17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.14.2. Product Portfolio
17.3.14.3. Financial Overview
17.3.14.4. SWOT Analysis
17.3.14.5. Strategic Overview
Table 01. Global Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 02. Global Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 03. Global Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 04. Global Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 05. Global Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 06. Global Vaccines Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 07. North America Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 08. North America Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 09. North America Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 10. North America Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 11. North America Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 12. Europe Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 13. Europe Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 14. Europe Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 15. Europe Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 16. Europe Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 17. Europe Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 18. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 19. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 20. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 21. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 22. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 23. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 24. Latin America Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 25. Latin America Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 26. Latin America Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 27. Latin America Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 28. Latin America Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 29. Latin America Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 30. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 31. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 32. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 33. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 34. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 35. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031